menu
    • menu
    [{"orgOrder":0,"company":"Amir Moradi","sponsor":"Allergan","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Onabotulinumtoxin A","moa":"ACh release","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Amir Moradi","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amir Moradi \/ Allergan","highestDevelopmentStatusID":"11","companyTruncated":"Amir Moradi \/ Allergan"},{"orgOrder":0,"company":"Alberto Espay","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Droxidopa","moa":"Adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Alberto Espay","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alberto Espay \/ H. Lundbeck AS","highestDevelopmentStatusID":"11","companyTruncated":"Alberto Espay \/ H. Lundbeck AS"},{"orgOrder":0,"company":"University of Alberta","sponsor":"University Hospital Foundation | Institute of Health Economics, Canada | Alberta Health services","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Midodrine","moa":"Adrenergic receptor alpha-1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"University of Alberta","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Alberta \/ University Hospital Foundation | Institute of Health Economics, Canada | Alberta Health services","highestDevelopmentStatusID":"11","companyTruncated":"University of Alberta \/ University Hospital Foundation | Institute of Health Economics, Canada | Alberta Health services"},{"orgOrder":0,"company":"Genuine Research Center, Egypt","sponsor":"Nerhadou International","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"EGYPT","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Nerkardou","moa":"Adrenergic-beta-1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Genuine Research Center, Egypt","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"Genuine Research Center, Egypt \/ Nerhadou International","highestDevelopmentStatusID":"11","companyTruncated":"Genuine Research Center, Egypt \/ Nerhadou International"},{"orgOrder":0,"company":"Yerevan State Medical University","sponsor":"Servier","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ARMENIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Perindopril","moa":"Angiotensin-converting enzyme","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Yerevan State Medical University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yerevan State Medical University \/ Servier","highestDevelopmentStatusID":"11","companyTruncated":"Yerevan State Medical University \/ Servier"},{"orgOrder":0,"company":"Academisch Ziekenhuis Maastricht","sponsor":"ZonMw","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Perindopril","moa":"Angiotensin-converting enzyme","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Academisch Ziekenhuis Maastricht","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Academisch Ziekenhuis Maastricht \/ ZonMw","highestDevelopmentStatusID":"11","companyTruncated":"Academisch Ziekenhuis Maastricht \/ ZonMw"},{"orgOrder":0,"company":"Menarini","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ITALY","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Zofenopril","moa":"antihypertensives (ACE inhibitors)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Menarini","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Menarini \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Menarini \/ Undisclosed"},{"orgOrder":0,"company":"Menarini","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ITALY","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Zofenopril","moa":"antihypertensives (ACE inhibitors)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Menarini","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Menarini \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Menarini \/ Undisclosed"},{"orgOrder":0,"company":"Valleywise Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Enoxaparin Sodium","moa":"Antithrombin-III","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Valleywise Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Valleywise Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Valleywise Health \/ Undisclosed"},{"orgOrder":0,"company":"Boston Scientific","sponsor":"National PERT Consortium, Inc. | University Medical Center Mainz","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Heparin Sodium","moa":"Antithrombin-III","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Boston Scientific","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boston Scientific \/ National PERT Consortium, Inc. | University Medical Center Mainz","highestDevelopmentStatusID":"11","companyTruncated":"Boston Scientific \/ National PERT Consortium, Inc. | University Medical Center Mainz"},{"orgOrder":0,"company":"Boston Scientific","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Heparin Sodium","moa":"Antithrombin-III","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Boston Scientific","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Boston Scientific \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Boston Scientific \/ Undisclosed"},{"orgOrder":0,"company":"Kaiser Permanente","sponsor":"Esperion Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Bempedoic Acid","moa":"ATP-citrate synthase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Kaiser Permanente","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kaiser Permanente \/ Esperion Therapeutics","highestDevelopmentStatusID":"11","companyTruncated":"Kaiser Permanente \/ Esperion Therapeutics"},{"orgOrder":0,"company":"Neutec Ar-Ge San ve Tic A.?","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"TURKEY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Metoprolol Tartrate","moa":"Beta-1 adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Neutec Ar-Ge San ve Tic A.?","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Neutec Ar-Ge San ve Tic A.? \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Neutec Ar-Ge San ve Tic A.? \/ Undisclosed"},{"orgOrder":0,"company":"Menarini","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ITALY","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Nebivolol","moa":"Beta-2 adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Menarini","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Menarini \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Menarini \/ Undisclosed"},{"orgOrder":0,"company":"Menarini","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ITALY","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Nebivolol","moa":"Beta-2 adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Menarini","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Menarini \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Menarini \/ Undisclosed"},{"orgOrder":0,"company":"University of California, San Diego","sponsor":"Grifols International","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Albumin","moa":"Bilirubin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"University of California, San Diego","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of California, San Diego \/ Grifols International","highestDevelopmentStatusID":"11","companyTruncated":"University of California, San Diego \/ Grifols International"},{"orgOrder":0,"company":"Vrije Universiteit Brussel","sponsor":"F. Hoffmann-La Roche | Jessa Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"BELGIUM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Acetazolamide","moa":"Carbonic anhydrase II | Carbonic anhydrase XII | Carbonic anhydrase IV | Carbonic anhydrase I","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Vrije Universiteit Brussel","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vrije Universiteit Brussel \/ F. Hoffmann-La Roche | Jessa Hospital","highestDevelopmentStatusID":"11","companyTruncated":"Vrije Universiteit Brussel \/ F. Hoffmann-La Roche | Jessa Hospital"},{"orgOrder":0,"company":"University of North Carolina","sponsor":"Colgate Palmolive","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Chlorhexidine","moa":"Cell membrane","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"University of North Carolina","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of North Carolina \/ Colgate Palmolive","highestDevelopmentStatusID":"11","companyTruncated":"University of North Carolina \/ Colgate Palmolive"},{"orgOrder":0,"company":"Hospital Sirio-Libanes","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"BRAZIL","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Edoxaban Tosylate","moa":"Coagulation factor X","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Hospital Sirio-Libanes","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hospital Sirio-Libanes \/ Daiichi Sankyo","highestDevelopmentStatusID":"11","companyTruncated":"Hospital Sirio-Libanes \/ Daiichi Sankyo"},{"orgOrder":0,"company":"University of Hong Kong","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"HONG KONG","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Rivaroxaban","moa":"Coagulation factor X","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"University of Hong Kong","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University of Hong Kong \/ Bayer AG","highestDevelopmentStatusID":"11","companyTruncated":"University of Hong Kong \/ Bayer AG"},{"orgOrder":0,"company":"Peshawar Institute of Cardiology","sponsor":"Getz Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"PAKISTAN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Rivaroxaban","moa":"Coagulation factor X","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Peshawar Institute of Cardiology","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Peshawar Institute of Cardiology \/ Getz Pharma","highestDevelopmentStatusID":"11","companyTruncated":"Peshawar Institute of Cardiology \/ Getz Pharma"},{"orgOrder":0,"company":"Asan Medical Center","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Rivaroxaban","moa":"Coagulation factor X","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Asan Medical Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Asan Medical Center \/ Bayer AG","highestDevelopmentStatusID":"11","companyTruncated":"Asan Medical Center \/ Bayer AG"},{"orgOrder":0,"company":"Science Valley Research Institute","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"BRAZIL","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Rivaroxaban","moa":"Coagulation factor X","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Science Valley Research Institute","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Science Valley Research Institute \/ Bayer AG","highestDevelopmentStatusID":"11","companyTruncated":"Science Valley Research Institute \/ Bayer AG"},{"orgOrder":0,"company":"Drahomir Aujesky","sponsor":"University of Bern | Schweizerischer Nationalfonds | Leiden University Medical Center | The Ottawa Hospital | Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Rivaroxaban","moa":"Coagulation factor X","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Drahomir Aujesky","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Drahomir Aujesky \/ University of Bern | Schweizerischer Nationalfonds | Leiden University Medical Center | The Ottawa Hospital | Bayer AG","highestDevelopmentStatusID":"11","companyTruncated":"Drahomir Aujesky \/ University of Bern | Schweizerischer Nationalfonds | Leiden University Medical Center | The Ottawa Hospital | Bayer AG"},{"orgOrder":0,"company":"Canadian Medical and Surgical Knowledge Translation Research Group","sponsor":"HLS Therapeutics | Unity Health Toronto | Western University, Canada","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Canadian Medical and Surgical Knowledge Translation Research Group","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Canadian Medical and Surgical Knowledge Translation Research Group \/ HLS Therapeutics | Unity Health Toronto | Western University, Canada","highestDevelopmentStatusID":"11","companyTruncated":"Canadian Medical and Surgical Knowledge Translation Research Group \/ HLS Therapeutics | Unity Health Toronto | Western University, Canada"},{"orgOrder":0,"company":"University of California, Los Angeles","sponsor":"American Heart Association | Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Macitentan","moa":"Endothelin receptor, ET-A\/ET-B","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"University of California, Los Angeles","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of California, Los Angeles \/ American Heart Association | Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"11","companyTruncated":"University of California, Los Angeles \/ American Heart Association | Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Boston Scientific","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Polidocanol","moa":"Endothelium of blood vessels (Endothelium)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Boston Scientific","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Foam","sponsorNew":"Boston Scientific \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Boston Scientific \/ Undisclosed"},{"orgOrder":0,"company":"American Regent","sponsor":"Syed Hamza Mufarrih","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2025","type":"Inapplicable","leadProduct":"Ferric Carboxymaltose","moa":"Fe","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"American Regent","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"American Regent \/ Syed Hamza Mufarrih","highestDevelopmentStatusID":"11","companyTruncated":"American Regent \/ Syed Hamza Mufarrih"},{"orgOrder":0,"company":"CSL","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"AUSTRALIA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Ferric Carboxymaltose","moa":"Fe","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"CSL \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"CSL \/ Undisclosed"},{"orgOrder":0,"company":"Radha Gopalan","sponsor":"American Regent","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Inapplicable","leadProduct":"Ferric Carboxymaltose","moa":"Fe","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Radha Gopalan","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Radha Gopalan \/ American Regent","highestDevelopmentStatusID":"11","companyTruncated":"Radha Gopalan \/ American Regent"},{"orgOrder":0,"company":"Johns Hopkins University","sponsor":"GUERBET","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Gadopiclenol","moa":"gadolinium derivatives (principally for diagnostic use)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Johns Hopkins University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johns Hopkins University \/ GUERBET","highestDevelopmentStatusID":"11","companyTruncated":"Johns Hopkins University \/ GUERBET"},{"orgOrder":0,"company":"St. Antonius Hospital","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"DAPT","moa":"Gamma-secretase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"St. Antonius Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"St. Antonius Hospital \/ Daiichi Sankyo","highestDevelopmentStatusID":"11","companyTruncated":"St. Antonius Hospital \/ Daiichi Sankyo"},{"orgOrder":0,"company":"Canadian Medical and Surgical Knowledge Translation Research Group","sponsor":"Unity Health Toronto | Western University, Canada","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Semaglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Canadian Medical and Surgical Knowledge Translation Research Group","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Canadian Medical and Surgical Knowledge Translation Research Group \/ Unity Health Toronto | Western University, Canada","highestDevelopmentStatusID":"11","companyTruncated":"Canadian Medical and Surgical Knowledge Translation Research Group \/ Unity Health Toronto | Western University, Canada"},{"orgOrder":0,"company":"Seoul National University Bundang Hospital","sponsor":"Korea United Pharm. Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Atorvastatin","moa":"HMG-CoA reductase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Seoul National University Bundang Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Seoul National University Bundang Hospital \/ Korea United Pharm. Inc.","highestDevelopmentStatusID":"11","companyTruncated":"Seoul National University Bundang Hospital \/ Korea United Pharm. Inc."},{"orgOrder":0,"company":"Chong Kun Dang Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Atorvastatin","moa":"HMG-CoA reductase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Chong Kun Dang Pharm","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chong Kun Dang Pharm \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Chong Kun Dang Pharm \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Atorvastatin","moa":"HMG-CoA reductase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Organon","sponsor":"IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Atorvastatin","moa":"HMG-CoA reductase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Organon \/ IQVIA","highestDevelopmentStatusID":"11","companyTruncated":"Organon \/ IQVIA"},{"orgOrder":0,"company":"Md. Alimur Reza","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Atorvastatin","moa":"HMG-CoA reductase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Md. Alimur Reza","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Md. Alimur Reza \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Md. Alimur Reza \/ Undisclosed"},{"orgOrder":0,"company":"Sichuan Provincial People's Hospital","sponsor":"Science and Technology Department, Sichuan Province","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Atorvastatin","moa":"HMG-CoA reductase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Sichuan Provincial People's Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sichuan Provincial People's Hospital \/ Science and Technology Department, Sichuan Province","highestDevelopmentStatusID":"11","companyTruncated":"Sichuan Provincial People's Hospital \/ Science and Technology Department, Sichuan Province"},{"orgOrder":0,"company":"Korea University Anam Hospital","sponsor":"Daewon Pharm. Co., Ltd | Samjin Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Pitavastatin","moa":"HMG-CoA reductase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Korea University Anam Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Korea University Anam Hospital \/ Daewon Pharm. Co., Ltd | Samjin Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"Korea University Anam Hospital \/ Daewon Pharm. Co., Ltd | Samjin Pharmaceutical"},{"orgOrder":0,"company":"JW Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Pitavastatin","moa":"HMG-CoA reductase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"JW Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"JW Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"JW Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Korea University Anam Hospital","sponsor":"Yuhan Corporation | Hanmi Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Rosuvastatin Calcium","moa":"HMG-CoA reductase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Korea University Anam Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Korea University Anam Hospital \/ Yuhan Corporation | Hanmi Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"Korea University Anam Hospital \/ Yuhan Corporation | Hanmi Pharmaceutical"},{"orgOrder":0,"company":"Seung-Whan Lee, M.D., Ph.D.","sponsor":"Yuhan Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Statin","moa":"HMG-CoA reductase (HMGCR)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Seung-Whan Lee, M.D., Ph.D.","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seung-Whan Lee, M.D., Ph.D. \/ Yuhan Corporation","highestDevelopmentStatusID":"11","companyTruncated":"Seung-Whan Lee, M.D., Ph.D. \/ Yuhan Corporation"},{"orgOrder":0,"company":"Oneness Biotech","sponsor":"Taipei Veterans General Hospital | Taipei Medical University Shuang Ho Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"TAIWAN","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"ON101","moa":"Immune","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Oneness Biotech","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Cream","sponsorNew":"Oneness Biotech \/ Taipei Veterans General Hospital | Taipei Medical University Shuang Ho Hospital","highestDevelopmentStatusID":"11","companyTruncated":"Oneness Biotech \/ Taipei Veterans General Hospital | Taipei Medical University Shuang Ho Hospital"},{"orgOrder":0,"company":"First Affiliated Hospital of Wannan Medical College","sponsor":"Suzhou Municipal Hospital of Anhui Province | the Second of Affiliated Hospital of Wannan Medical College, Wuhu, China | Wuhu Hospital of Chinese Traditional Medicine | Wuhu First People\u2019s Hospital | Wuhu City Second People\u2019s Hospital | Xuancheng People\u2019s","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Plant Extract\/Herbal","year":"2025","type":"Inapplicable","leadProduct":"Shenfu","moa":"Immune","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"First Affiliated Hospital of Wannan Medical College","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"First Affiliated Hospital of Wannan Medical College \/ Suzhou Municipal Hospital of Anhui Province | the Second of Affiliated Hospital of Wannan Medical College, Wuhu, China | Wuhu Hospital of Chinese Traditional Medicine | Wuhu First People\u2019s Hospital | Wuhu City Second People\u2019s Hospital | Xuancheng People\u2019s","highestDevelopmentStatusID":"11","companyTruncated":"First Affiliated Hospital of Wannan Medical College \/ Suzhou Municipal Hospital of Anhui Province | the Second of Affiliated Hospital of Wannan Medical College, Wuhu, China | Wuhu Hospital of Chinese Traditional Medicine | Wuhu First People\u2019s Hospital | Wuhu City Second People\u2019s Hospital | Xuancheng People\u2019s"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"HONG KONG","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Shexiang Baoxin","moa":"Immune","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Pill","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Amsterdam UMC, VUmc","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Sotatercept","moa":"Inhibin beta A chain","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Amsterdam UMC, VUmc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amsterdam UMC, VUmc \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"Amsterdam UMC, VUmc \/ Merck & Co"},{"orgOrder":0,"company":"University of Alberta","sponsor":"MERCK CANADA INC | Alberta Health services","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Sotatercept","moa":"Inhibin beta A chain","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"University of Alberta","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Alberta \/ MERCK CANADA INC | Alberta Health services","highestDevelopmentStatusID":"11","companyTruncated":"University of Alberta \/ MERCK CANADA INC | Alberta Health services"},{"orgOrder":0,"company":"Medicure","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tirofiban Hydrochloride Monohydrate","moa":"||Integrin alpha-IIb\/beta-3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Medicure","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Medicure \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Medicure \/ Undisclosed"},{"orgOrder":0,"company":"Hannover Medical School","sponsor":"Norgine","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Inapplicable","leadProduct":"Ferric Maltol","moa":"Integrin-beta-3 substrate","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Hannover Medical School","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hannover Medical School \/ Norgine","highestDevelopmentStatusID":"11","companyTruncated":"Hannover Medical School \/ Norgine"},{"orgOrder":0,"company":"CMP Development","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Spironolactone","moa":"Mineralocorticoid receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"CMP Development","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"CMP Development \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"CMP Development \/ Undisclosed"},{"orgOrder":0,"company":"University of Oklahoma","sponsor":"University of Pennsylvania | Oklahoma Medical Research Foundation | Elysium Health","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Nicotinamide Riboside","moa":"NAD","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"University of Oklahoma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Oklahoma \/ University of Pennsylvania | Oklahoma Medical Research Foundation | Elysium Health","highestDevelopmentStatusID":"11","companyTruncated":"University of Oklahoma \/ University of Pennsylvania | Oklahoma Medical Research Foundation | Elysium Health"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Sacubitril Sodium","moa":"Neprilysin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Sacubitril Sodium","moa":"Neprilysin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Hospital Universitario Dr. Jose E. Gonzalez","sponsor":"Ever Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Cerebrolysin","moa":"Neurotrophic factor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Hospital Universitario Dr. Jose E. Gonzalez","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Hospital Universitario Dr. Jose E. Gonzalez \/ Ever Pharma","highestDevelopmentStatusID":"11","companyTruncated":"Hospital Universitario Dr. Jose E. Gonzalez \/ Ever Pharma"},{"orgOrder":0,"company":"Samjin pharm Co. Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Samjin pharm Co. Ltd","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Samjin pharm Co. Ltd \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Samjin pharm Co. Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Duke University","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Inclisiran","moa":"PCSK9 mRNA","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Duke University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Duke University \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"11","companyTruncated":"Duke University \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"Inclisiran Sodium","moa":"PCSK9 mRNA","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Inclisiran Sodium","moa":"PCSK9 mRNA","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Inclisiran Sodium","moa":"PCSK9 mRNA","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Inclisiran Sodium","moa":"PCSK9 mRNA","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Inclisiran Sodium","moa":"PCSK9 mRNA","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"University of California, San Diego","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"Inclisiran Sodium","moa":"PCSK9 mRNA","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"University of California, San Diego","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of California, San Diego \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"11","companyTruncated":"University of California, San Diego \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Beijing Tiantan Hospital","sponsor":"CSPC Ouyi Pharmaceutical Co., Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Pentoxifylline","moa":"Adenosine A2 receptor | 3',5'-cyclic phosphodiesterase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Beijing Tiantan Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Beijing Tiantan Hospital \/ CSPC Ouyi Pharmaceutical Co., Ltd","highestDevelopmentStatusID":"11","companyTruncated":"Beijing Tiantan Hospital \/ CSPC Ouyi Pharmaceutical Co., Ltd"},{"orgOrder":0,"company":"Seoul National University Bundang Hospital","sponsor":"Daewon Pharm. Co., Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Choline Fenofibrate","moa":"Peroxisome proliferator-activated receptor alpha","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Seoul National University Bundang Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seoul National University Bundang Hospital \/ Daewon Pharm. Co., Ltd","highestDevelopmentStatusID":"11","companyTruncated":"Seoul National University Bundang Hospital \/ Daewon Pharm. Co., Ltd"},{"orgOrder":0,"company":"Gyeongsang National University Hospital","sponsor":"Korea Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Cilostazol","moa":"Phosphodiesterase 3A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Gyeongsang National University Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Gyeongsang National University Hospital \/ Korea Otsuka Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"Gyeongsang National University Hospital \/ Korea Otsuka Pharmaceutical"},{"orgOrder":0,"company":"SK Chemicals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Renexin","moa":"Platelet aggregation","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"SK Chemicals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SK Chemicals \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"SK Chemicals \/ Undisclosed"},{"orgOrder":0,"company":"Tulane University School of Medicine","sponsor":"University of Washington | Marrek, INC | Sanofi | Preventice | McKesson","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Dronedarone Hydrochloride","moa":"Potassium\/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Tulane University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tulane University School of Medicine \/ University of Washington | Marrek, INC | Sanofi | Preventice | McKesson","highestDevelopmentStatusID":"11","companyTruncated":"Tulane University School of Medicine \/ University of Washington | Marrek, INC | Sanofi | Preventice | McKesson"},{"orgOrder":0,"company":"American Heart Association","sponsor":"Duke Clinical Research Institute | Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Dronedarone Hydrochloride","moa":"Potassium\/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"American Heart Association","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"American Heart Association \/ Duke Clinical Research Institute | Sanofi","highestDevelopmentStatusID":"11","companyTruncated":"American Heart Association \/ Duke Clinical Research Institute | Sanofi"},{"orgOrder":0,"company":"Daejeon St. Mary's hospital","sponsor":"Jeil Pharmaceutical Co., Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Lansoprazole","moa":"Potassium-transporting ATPase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Daejeon St. Mary's hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Daejeon St. Mary's hospital \/ Jeil Pharmaceutical Co., Ltd","highestDevelopmentStatusID":"11","companyTruncated":"Daejeon St. Mary's hospital \/ Jeil Pharmaceutical Co., Ltd"},{"orgOrder":0,"company":"AOP Orphan","sponsor":"ANOVA CRO | PharmaLex | Aixial s.r.o. | GCP-Service International","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"AUSTRIA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"AOP Orphan","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AOP Orphan \/ ANOVA CRO | PharmaLex | Aixial s.r.o. | GCP-Service International","highestDevelopmentStatusID":"11","companyTruncated":"AOP Orphan \/ ANOVA CRO | PharmaLex | Aixial s.r.o. | GCP-Service International"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Lung Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"United Therapeutics \/ Lung Biotechnology","highestDevelopmentStatusID":"11","companyTruncated":"United Therapeutics \/ Lung Biotechnology"},{"orgOrder":0,"company":"University Hospital, Caen","sponsor":"Terumo","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Cangrelor","moa":"Purinergic receptor P2Y12","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"University Hospital, Caen","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospital, Caen \/ Terumo","highestDevelopmentStatusID":"11","companyTruncated":"University Hospital, Caen \/ Terumo"},{"orgOrder":0,"company":"Harbin Medical University","sponsor":"Chinese Society of Cardiology | Lepu Medical Technology","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Clopidogrel","moa":"Purinergic receptor P2Y12","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Harbin Medical University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Harbin Medical University \/ Chinese Society of Cardiology | Lepu Medical Technology","highestDevelopmentStatusID":"11","companyTruncated":"Harbin Medical University \/ Chinese Society of Cardiology | Lepu Medical Technology"},{"orgOrder":0,"company":"Insel Gruppe AG, University Hospital Bern","sponsor":"Sahajanand Medical Technologies Limited","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Clopidogrel","moa":"Purinergic receptor P2Y12","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Insel Gruppe AG, University Hospital Bern","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Insel Gruppe AG, University Hospital Bern \/ Sahajanand Medical Technologies Limited","highestDevelopmentStatusID":"11","companyTruncated":"Insel Gruppe AG, University Hospital Bern \/ Sahajanand Medical Technologies Limited"},{"orgOrder":0,"company":"Kindai University","sponsor":"Boston Scientific","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Prasugrel","moa":"Purinergic receptor P2Y12","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Kindai University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kindai University \/ Boston Scientific","highestDevelopmentStatusID":"11","companyTruncated":"Kindai University \/ Boston Scientific"},{"orgOrder":0,"company":"Gyeongsang National University Hospital","sponsor":"U&I Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Prasugrel","moa":"Purinergic receptor P2Y12","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Gyeongsang National University Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gyeongsang National University Hospital \/ U&I Corporation","highestDevelopmentStatusID":"11","companyTruncated":"Gyeongsang National University Hospital \/ U&I Corporation"},{"orgOrder":0,"company":"Research Maatschap Cardiologen Rotterdam Zuid","sponsor":"Abbott Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Prasugrel","moa":"Purinergic receptor P2Y12","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Research Maatschap Cardiologen Rotterdam Zuid","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Research Maatschap Cardiologen Rotterdam Zuid \/ Abbott Laboratories","highestDevelopmentStatusID":"11","companyTruncated":"Research Maatschap Cardiologen Rotterdam Zuid \/ Abbott Laboratories"},{"orgOrder":0,"company":"Peking University Third Hospital","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ticagrelor","moa":"Purinergic receptor P2Y12","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Peking University Third Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Peking University Third Hospital \/ AstraZeneca","highestDevelopmentStatusID":"11","companyTruncated":"Peking University Third Hospital \/ AstraZeneca"},{"orgOrder":0,"company":"University Medical Center Utrecht","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ticagrelor","moa":"Purinergic receptor P2Y12","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"University Medical Center Utrecht","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University Medical Center Utrecht \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"University Medical Center Utrecht \/ Undisclosed"},{"orgOrder":0,"company":"Elixir Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Novolimus","moa":"Serine\/threonine-protein kinase mTOR (mTOR)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Elixir Medical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Elixir Medical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Elixir Medical \/ Undisclosed"},{"orgOrder":0,"company":"Yuhan Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Sarpogrelate","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Yuhan Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yuhan Corporation \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Yuhan Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Yuhan Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Sarpogrelate","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Yuhan Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yuhan Corporation \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Yuhan Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Scripps Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Scripps Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Scripps Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Scripps Health \/ Undisclosed"},{"orgOrder":0,"company":"Johns Hopkins University","sponsor":"University of California, Los Angeles | Brett Boyer Foundation | AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Johns Hopkins University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johns Hopkins University \/ University of California, Los Angeles | Brett Boyer Foundation | AstraZeneca","highestDevelopmentStatusID":"11","companyTruncated":"Johns Hopkins University \/ University of California, Los Angeles | Brett Boyer Foundation | AstraZeneca"},{"orgOrder":0,"company":"TIMI Study Group","sponsor":"AstraZeneca | Worldwide Clinical Trials","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"TIMI Study Group","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TIMI Study Group \/ AstraZeneca | Worldwide Clinical Trials","highestDevelopmentStatusID":"11","companyTruncated":"TIMI Study Group \/ AstraZeneca | Worldwide Clinical Trials"},{"orgOrder":0,"company":"University of Rochester","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"University of Rochester","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University of Rochester \/ AstraZeneca","highestDevelopmentStatusID":"11","companyTruncated":"University of Rochester \/ AstraZeneca"},{"orgOrder":0,"company":"Frank Ruschitzka","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Frank Ruschitzka","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Frank Ruschitzka \/ AstraZeneca","highestDevelopmentStatusID":"11","companyTruncated":"Frank Ruschitzka \/ AstraZeneca"},{"orgOrder":0,"company":"Duk-Woo Park","sponsor":"CardioVascular Research Foundation, Korea | Daewoong Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Enavogliflozin","moa":"SLC5A2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Duk-Woo Park","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Duk-Woo Park \/ CardioVascular Research Foundation, Korea | Daewoong Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"Duk-Woo Park \/ CardioVascular Research Foundation, Korea | Daewoong Pharmaceutical"},{"orgOrder":0,"company":"Wake Forest University Health Sciences","sponsor":"Merz Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Incobotulinumtoxin A","moa":"SNAP25","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Wake Forest University Health Sciences","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wake Forest University Health Sciences \/ Merz Pharma","highestDevelopmentStatusID":"11","companyTruncated":"Wake Forest University Health Sciences \/ Merz Pharma"},{"orgOrder":0,"company":"Rambam Health Care Campus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Furosemide","moa":"Sodium-(potassium)-chloride cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Rambam Health Care Campus","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rambam Health Care Campus \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Rambam Health Care Campus \/ Undisclosed"},{"orgOrder":0,"company":"Heart Center Research, LLC","sponsor":"Boston Scientific","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Furosemide","moa":"Sodium-(potassium)-chloride cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Heart Center Research, LLC","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Heart Center Research, LLC \/ Boston Scientific","highestDevelopmentStatusID":"11","companyTruncated":"Heart Center Research, LLC \/ Boston Scientific"},{"orgOrder":0,"company":"University of Florida","sponsor":"SQ Innovation","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Furosemide","moa":"Sodium-(potassium)-chloride cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"University of Florida","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"University of Florida \/ SQ Innovation","highestDevelopmentStatusID":"11","companyTruncated":"University of Florida \/ SQ Innovation"},{"orgOrder":0,"company":"Unity Health Toronto","sponsor":"Canadian Medical and Surgical Knowledge Translation Research Group | Boehringer Ingelheim GmbH | Applied Health Research Centre","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Unity Health Toronto","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Unity Health Toronto \/ Canadian Medical and Surgical Knowledge Translation Research Group | Boehringer Ingelheim GmbH | Applied Health Research Centre","highestDevelopmentStatusID":"11","companyTruncated":"Unity Health Toronto \/ Canadian Medical and Surgical Knowledge Translation Research Group | Boehringer Ingelheim GmbH | Applied Health Research Centre"},{"orgOrder":0,"company":"UT Southwestern Medical Center","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"UT Southwestern Medical Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UT Southwestern Medical Center \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"11","companyTruncated":"UT Southwestern Medical Center \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Heidelberg University","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Riociguat","moa":"Soluble guanylate cyclase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Heidelberg University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Heidelberg University \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"Heidelberg University \/ Merck & Co"},{"orgOrder":0,"company":"Josef Stehlik","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Vericiguat","moa":"Soluble guanylate cyclase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Josef Stehlik","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Josef Stehlik \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"Josef Stehlik \/ Merck & Co"},{"orgOrder":0,"company":"University of California, Los Angeles","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Evolocumab","moa":"Subtilisin\/kexin type 9","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"University of California, Los Angeles","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"University of California, Los Angeles \/ Amgen Inc","highestDevelopmentStatusID":"11","companyTruncated":"University of California, Los Angeles \/ Amgen Inc"},{"orgOrder":0,"company":"Yonsei University","sponsor":"Daewoong Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Evolocumab","moa":"Subtilisin\/kexin type 9","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Yonsei University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yonsei University \/ Daewoong Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"Yonsei University \/ Daewoong Pharmaceutical"},{"orgOrder":0,"company":"Hanyang University Seoul Hospital","sponsor":"DOTTER Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Evolocumab","moa":"Subtilisin\/kexin type 9","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Hanyang University Seoul Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hanyang University Seoul Hospital \/ DOTTER Inc.","highestDevelopmentStatusID":"11","companyTruncated":"Hanyang University Seoul Hospital \/ DOTTER Inc."},{"orgOrder":0,"company":"Assistance Publique \u2013 H\u00f4pitaux de Paris","sponsor":"Action Research Group | Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Evolocumab","moa":"Subtilisin\/kexin type 9","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Assistance Publique \u2013 H\u00f4pitaux de Paris","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ Action Research Group | Amgen Inc","highestDevelopmentStatusID":"11","companyTruncated":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ Action Research Group | Amgen Inc"},{"orgOrder":0,"company":"Hamad Medical Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"QATAR","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Evolocumab","moa":"Subtilisin\/kexin type 9","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Hamad Medical Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hamad Medical Corporation \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Hamad Medical Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Canadian Medical and Surgical Knowledge Translation Research Group","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Evolocumab","moa":"Subtilisin\/kexin type 9","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Canadian Medical and Surgical Knowledge Translation Research Group","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Canadian Medical and Surgical Knowledge Translation Research Group \/ Amgen Inc","highestDevelopmentStatusID":"11","companyTruncated":"Canadian Medical and Surgical Knowledge Translation Research Group \/ Amgen Inc"},{"orgOrder":0,"company":"Brigham and Women's Hospital","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Evolocumab","moa":"Subtilisin\/kexin type 9","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Brigham and Women's Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Brigham and Women's Hospital \/ Amgen Inc","highestDevelopmentStatusID":"11","companyTruncated":"Brigham and Women's Hospital \/ Amgen Inc"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Colorado Prevention Center","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Evolocumab","moa":"Subtilisin\/kexin type 9","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Colorado Prevention Center","highestDevelopmentStatusID":"11","companyTruncated":"Amgen Inc \/ Colorado Prevention Center"},{"orgOrder":0,"company":"Leonardo Clavijo","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Evolocumab","moa":"Subtilisin\/kexin type 9","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Leonardo Clavijo","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Leonardo Clavijo \/ Amgen Inc","highestDevelopmentStatusID":"11","companyTruncated":"Leonardo Clavijo \/ Amgen Inc"},{"orgOrder":0,"company":"Leonardo Clavijo","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Evolocumab","moa":"Subtilisin\/kexin type 9","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Leonardo Clavijo","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Leonardo Clavijo \/ Amgen Inc","highestDevelopmentStatusID":"11","companyTruncated":"Leonardo Clavijo \/ Amgen Inc"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Argatroban","moa":"Thrombin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mitsubishi Tanabe Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Mitsubishi Tanabe Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Zuyderland Medisch Centrum","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dabigatran Etexilate Mesylate","moa":"Thrombin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Zuyderland Medisch Centrum","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zuyderland Medisch Centrum \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"11","companyTruncated":"Zuyderland Medisch Centrum \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Second Affiliated Hospital, Guangxi Medical University","sponsor":"CSPC Pharmaceutical Group","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Tenecteplase","moa":"Tissue-type plasminogen activator","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Second Affiliated Hospital, Guangxi Medical University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Second Affiliated Hospital, Guangxi Medical University \/ CSPC Pharmaceutical Group","highestDevelopmentStatusID":"11","companyTruncated":"Second Affiliated Hospital, Guangxi Medical University \/ CSPC Pharmaceutical Group"},{"orgOrder":0,"company":"Cedars-Sinai","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Tenecteplase","moa":"Tissue-type plasminogen activator","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Cedars-Sinai","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection, Powder, Lyophilized","sponsorNew":"Cedars-Sinai \/ Genentech","highestDevelopmentStatusID":"11","companyTruncated":"Cedars-Sinai \/ Genentech"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tafamidis","moa":"Transthyretin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"CHA University","sponsor":"Biotronik","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Plant Extract\/Herbal","year":"2024","type":"Inapplicable","leadProduct":"Colchicine","moa":"Tubulin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"CHA University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CHA University \/ Biotronik","highestDevelopmentStatusID":"11","companyTruncated":"CHA University \/ Biotronik"},{"orgOrder":0,"company":"Vivek Reddy","sponsor":"Boston Scientific","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Plant Extract\/Herbal","year":"2025","type":"Inapplicable","leadProduct":"Colchicine","moa":"Tubulin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Vivek Reddy","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vivek Reddy \/ Boston Scientific","highestDevelopmentStatusID":"11","companyTruncated":"Vivek Reddy \/ Boston Scientific"},{"orgOrder":0,"company":"Chong Kun Dang Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Candesartan Cilexetil","moa":"Type-1 angiotensin II receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Chong Kun Dang Pharm","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chong Kun Dang Pharm \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Chong Kun Dang Pharm \/ Undisclosed"},{"orgOrder":0,"company":"Boryung Pharmaceutical Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Fimasartan","moa":"Type-1 angiotensin II receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Boryung Pharmaceutical Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Boryung Pharmaceutical Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Boryung Pharmaceutical Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Boryung Pharmaceutical Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Fimasartan","moa":"Type-1 angiotensin II receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Boryung Pharmaceutical Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Boryung Pharmaceutical Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Boryung Pharmaceutical Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Boryung Pharmaceutical Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Fimasartan","moa":"Type-1 angiotensin II receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Boryung Pharmaceutical Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Boryung Pharmaceutical Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Boryung Pharmaceutical Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Boryung Pharmaceutical Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Fimasartan","moa":"Type-1 angiotensin II receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Boryung Pharmaceutical Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Boryung Pharmaceutical Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Boryung Pharmaceutical Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Boryung Pharmaceutical Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Fimasartan","moa":"Type-1 angiotensin II receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Boryung Pharmaceutical Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Boryung Pharmaceutical Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Boryung Pharmaceutical Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Chong Kun Dang Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Telmisartan","moa":"Type-1 angiotensin II receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Chong Kun Dang Pharm","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chong Kun Dang Pharm \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Chong Kun Dang Pharm \/ Undisclosed"},{"orgOrder":0,"company":"Yuhan Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Telmisartan","moa":"Type-1 angiotensin II receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Yuhan Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yuhan Corporation \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Yuhan Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Cell Biopeutics Resources","sponsor":"Stempeutics | National University of Malaysia","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"MALAYSIA","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Allogeneic Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Cell Biopeutics Resources","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cell Biopeutics Resources \/ Stempeutics | National University of Malaysia","highestDevelopmentStatusID":"11","companyTruncated":"Cell Biopeutics Resources \/ Stempeutics | National University of Malaysia"},{"orgOrder":0,"company":"Cell Biopeutics Resources","sponsor":"Stempeutics | National University of Malaysia","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"MALAYSIA","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Allogeneic Mesenchymal Stromal Cell","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Cell Biopeutics Resources","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cell Biopeutics Resources \/ Stempeutics | National University of Malaysia","highestDevelopmentStatusID":"11","companyTruncated":"Cell Biopeutics Resources \/ Stempeutics | National University of Malaysia"},{"orgOrder":0,"company":"Hamad Medical Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"QATAR","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Acetylsalicilic Acid","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Hamad Medical Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hamad Medical Corporation \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Hamad Medical Corporation \/ Undisclosed"},{"orgOrder":0,"company":"National University Hospital, Singapore","sponsor":"Wellcome Leap Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SINGAPORE","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"CAS 328-50-7","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"National University Hospital, Singapore","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National University Hospital, Singapore \/ Wellcome Leap Inc.","highestDevelopmentStatusID":"11","companyTruncated":"National University Hospital, Singapore \/ Wellcome Leap Inc."},{"orgOrder":0,"company":"WakeMed Health and Hospitals","sponsor":"Helios Cardio","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Cardiamend","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"WakeMed Health and Hospitals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"WakeMed Health and Hospitals \/ Helios Cardio","highestDevelopmentStatusID":"11","companyTruncated":"WakeMed Health and Hospitals \/ Helios Cardio"},{"orgOrder":0,"company":"Chinese PLA General Hospital","sponsor":"DALIAN ZHEN AO BIO TECH CO LTD","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Cardiomyopeptidin","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Chinese PLA General Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chinese PLA General Hospital \/ Dalian Zhen Ao Bio Tech Co Ltd","highestDevelopmentStatusID":"11","companyTruncated":"Chinese PLA General Hospital \/ Dalian Zhen Ao Bio Tech Co Ltd"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Quest Medical, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Cardioplexol","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Washington University School of Medicine \/ Quest Medical, Inc","highestDevelopmentStatusID":"11","companyTruncated":"Washington University School of Medicine \/ Quest Medical, Inc"},{"orgOrder":0,"company":"RDC Clinical","sponsor":"Bio-gen Extracts","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"AUSTRALIA","productType":"Plant Extract\/Herbal","year":"2025","type":"Inapplicable","leadProduct":"Carotenoids","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"RDC Clinical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RDC Clinical \/ Bio-gen Extracts","highestDevelopmentStatusID":"11","companyTruncated":"RDC Clinical \/ Bio-gen Extracts"},{"orgOrder":0,"company":"Beijing Tiantan Hospital","sponsor":"Tianjin Tasly Group","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Cerebralcare","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Beijing Tiantan Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Pill","sponsorNew":"Beijing Tiantan Hospital \/ Tianjin Tasly Group","highestDevelopmentStatusID":"11","companyTruncated":"Beijing Tiantan Hospital \/ Tianjin Tasly Group"},{"orgOrder":0,"company":"Radboud University Medical Center","sponsor":"ZonMw | Academisch Ziekenhuis Groningen | Rijnstate Hospital | Bernhoven Hospital | Canisius-Wilhelmina Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"CYP2C19 Genotyping","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Radboud University Medical Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Radboud University Medical Center \/ ZonMw | Academisch Ziekenhuis Groningen | Rijnstate Hospital | Bernhoven Hospital | Canisius-Wilhelmina Hospital","highestDevelopmentStatusID":"11","companyTruncated":"Radboud University Medical Center \/ ZonMw | Academisch Ziekenhuis Groningen | Rijnstate Hospital | Bernhoven Hospital | Canisius-Wilhelmina Hospital"},{"orgOrder":0,"company":"Nanjing Baixinyu Pharmaceutical Co.","sponsor":"Xing'an League People's Hospital | Suzhou First People's Hospital | Nanyang nanshi Hospital | Ruijun Ji","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Edaravone","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Nanjing Baixinyu Pharmaceutical Co.","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nanjing Baixinyu Pharmaceutical Co. \/ Xing'an League People's Hospital | Suzhou First People's Hospital | Nanyang nanshi Hospital | Ruijun Ji","highestDevelopmentStatusID":"11","companyTruncated":"Nanjing Baixinyu Pharmaceutical Co. \/ Xing'an League People's Hospital | Suzhou First People's Hospital | Nanyang nanshi Hospital | Ruijun Ji"},{"orgOrder":0,"company":"The Jackson Laboratory","sponsor":"UConn Health | Icahn School of Medicine at Mount Sinai | Weill Medical College of Cornell University | University of Chicago | National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Flu Vaccine","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"The Jackson Laboratory","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The Jackson Laboratory \/ UConn Health | Icahn School of Medicine at Mount Sinai | Weill Medical College of Cornell University | University of Chicago | National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"11","companyTruncated":"The Jackson Laboratory \/ UConn Health | Icahn School of Medicine at Mount Sinai | Weill Medical College of Cornell University | University of Chicago | National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"Academisch Medisch Centrum - Universiteit van Amsterdam","sponsor":"ZonMw","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Hyperbaric Oxygen","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Academisch Medisch Centrum - Universiteit van Amsterdam","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Academisch Medisch Centrum - Universiteit van Amsterdam \/ ZonMw","highestDevelopmentStatusID":"11","companyTruncated":"Academisch Medisch Centrum - Universiteit van Amsterdam \/ ZonMw"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"JNJ-67896049","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"KJX839","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Pharmasoft","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Emoxypine Succinate","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Pharmasoft","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Pharmasoft \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Pharmasoft \/ Undisclosed"},{"orgOrder":0,"company":"Pharmasoft","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Emoxypine Succinate","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Pharmasoft","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Pharmasoft \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Pharmasoft \/ Undisclosed"},{"orgOrder":0,"company":"The George Institute","sponsor":"Victor Chang Cardiac Research Institute | St Vincent's Centre for Applied Medical Research | Royal Prince Alfred Hospital, Sydney","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"AUSTRALIA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Polydiuretic Therapy","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"The George Institute","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The George Institute \/ Victor Chang Cardiac Research Institute | St Vincent's Centre for Applied Medical Research | Royal Prince Alfred Hospital, Sydney","highestDevelopmentStatusID":"11","companyTruncated":"The George Institute \/ Victor Chang Cardiac Research Institute | St Vincent's Centre for Applied Medical Research | Royal Prince Alfred Hospital, Sydney"},{"orgOrder":0,"company":"Laboratoires des M\u00e9dicaments St\u00e9riles","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"PT-INR","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Laboratoires des M\u00e9dicaments St\u00e9riles","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laboratoires des M\u00e9dicaments St\u00e9riles \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Laboratoires des M\u00e9dicaments St\u00e9riles \/ Undisclosed"},{"orgOrder":0,"company":"Xuanwu Hospital, Beijing","sponsor":"Recomgen Biotech | Beijing Hospitals Authority","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Recombinant Human TNK-tPA","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Xuanwu Hospital, Beijing","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xuanwu Hospital, Beijing \/ Recomgen Biotech | Beijing Hospitals Authority","highestDevelopmentStatusID":"11","companyTruncated":"Xuanwu Hospital, Beijing \/ Recomgen Biotech | Beijing Hospitals Authority"},{"orgOrder":0,"company":"Ochsner Health System","sponsor":"Bracco","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Rubidium-82","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Ochsner Health System","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ochsner Health System \/ Bracco","highestDevelopmentStatusID":"11","companyTruncated":"Ochsner Health System \/ Bracco"},{"orgOrder":0,"company":"Hanlim Pharmaceuticals Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Vitis Vinifera Seed Dreid Extract","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Hanlim Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hanlim Pharmaceuticals Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Hanlim Pharmaceuticals Inc \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Famous Medical Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Wulingsan","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Jiangsu Famous Medical Technology","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Famous Medical Technology \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Jiangsu Famous Medical Technology \/ Undisclosed"},{"orgOrder":0,"company":"SPH Qingdao Growful Pharmacetical Co.,Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Plant Extract\/Herbal","year":"2025","type":"Inapplicable","leadProduct":"Yangxinshi","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"SPH Qingdao Growful Pharmacetical Co.,Ltd","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"SPH Qingdao Growful Pharmacetical Co.,Ltd \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"SPH Qingdao Growful Pharmacetical Co.,Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Queen Mary University of London","sponsor":"Closed Loop Medicine | Innovate UK","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Amlodipine","moa":"Voltage-gated L-type calcium channel","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Queen Mary University of London","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Queen Mary University of London \/ Closed Loop Medicine | Innovate UK","highestDevelopmentStatusID":"11","companyTruncated":"Queen Mary University of London \/ Closed Loop Medicine | Innovate UK"},{"orgOrder":0,"company":"Queen Mary University of London","sponsor":"Innovate UK | Closed Loop Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Amlodipine","moa":"Voltage-gated L-type calcium channel","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Queen Mary University of London","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Queen Mary University of London \/ Innovate UK | Closed Loop Medicine","highestDevelopmentStatusID":"11","companyTruncated":"Queen Mary University of London \/ Innovate UK | Closed Loop Medicine"},{"orgOrder":0,"company":"Shenzhen Ausa Pharmed Co.,Ltd","sponsor":"Peking University First Hospital | Second Affiliated Hospital, Nanchang University | The First People's Hospital of Lianyungang | The Affiliated Hospital Of Guizhou Medical University | Lianyungang Oriental Hospital | Tengzhou Central People's Hospital | ","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Amlodipine Besylate","moa":"Voltage-gated L-type calcium channel","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Shenzhen Ausa Pharmed Co.,Ltd","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shenzhen Ausa Pharmed Co.,Ltd \/ Peking University First Hospital | Second Affiliated Hospital, Nanchang University | The First People's Hospital of Lianyungang | The Affiliated Hospital Of Guizhou Medical University | Lianyungang Oriental Hospital | Tengzhou Central People's Hospital | ","highestDevelopmentStatusID":"11","companyTruncated":"Shenzhen Ausa Pharmed Co.,Ltd \/ Peking University First Hospital | Second Affiliated Hospital, Nanchang University | The First People's Hospital of Lianyungang | The Affiliated Hospital Of Guizhou Medical University | Lianyungang Oriental Hospital | Tengzhou Central People's Hospital | "},{"orgOrder":0,"company":"Shenzhen Ausa Pharmed Co.,Ltd","sponsor":"Peking University First Hospital | Second Affiliated Hospital, Nanchang University | The First People's Hospital of Lianyungang | The Affiliated Hospital Of Guizhou Medical University | Lianyungang Oriental Hospital | Tengzhou Central People's Hospital | ","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Amlodipine Besylate","moa":"Voltage-gated L-type calcium channel","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Shenzhen Ausa Pharmed Co.,Ltd","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shenzhen Ausa Pharmed Co.,Ltd \/ Peking University First Hospital | Second Affiliated Hospital, Nanchang University | The First People's Hospital of Lianyungang | The Affiliated Hospital Of Guizhou Medical University | Lianyungang Oriental Hospital | Tengzhou Central People's Hospital | ","highestDevelopmentStatusID":"11","companyTruncated":"Shenzhen Ausa Pharmed Co.,Ltd \/ Peking University First Hospital | Second Affiliated Hospital, Nanchang University | The First People's Hospital of Lianyungang | The Affiliated Hospital Of Guizhou Medical University | Lianyungang Oriental Hospital | Tengzhou Central People's Hospital | "},{"orgOrder":0,"company":"Brigham and Women's Hospital","sponsor":"Boehringer Ingelheim GmbH | Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Brigham and Women's Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Brigham and Women's Hospital \/ Boehringer Ingelheim GmbH | Eli Lilly","highestDevelopmentStatusID":"11","companyTruncated":"Brigham and Women's Hospital \/ Boehringer Ingelheim GmbH | Eli Lilly"},{"orgOrder":0,"company":"Brigham and Women's Hospital","sponsor":"Novo Nordisk","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Brigham and Women's Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Brigham and Women's Hospital \/ Novo Nordisk","highestDevelopmentStatusID":"11","companyTruncated":"Brigham and Women's Hospital \/ Novo Nordisk"},{"orgOrder":0,"company":"Spectrum Health - Lakeland","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Spectrum Health - Lakeland","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Spectrum Health - Lakeland \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Spectrum Health - Lakeland \/ Undisclosed"},{"orgOrder":0,"company":"OCEAN-SHD Study Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"OCEAN-SHD Study Group","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OCEAN-SHD Study Group \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"OCEAN-SHD Study Group \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Shanghai Zhongshan Hospital | Huashan Hospital | Shanghai 10th People's Hospital | Shanghai 6th People's Hospital | Shanghai General Hospital | Shanghai East Hospital | Longhua Hospital | Second Affiliated Hospital, Soochow University | Affiliated Hospita","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"HONG KONG","productType":"Plant Extract\/Herbal","year":"2025","type":"Inapplicable","leadProduct":"Shexiang Baoxin","moa":"Immune","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Pill","sponsorNew":"Hutchmed \/ Shanghai Zhongshan Hospital | Huashan Hospital | Shanghai 10th People's Hospital | Shanghai 6th People's Hospital | Shanghai General Hospital | Shanghai East Hospital | Longhua Hospital | Second Affiliated Hospital, Soochow University | Affiliated Hospita","highestDevelopmentStatusID":"11","companyTruncated":"Hutchmed \/ Shanghai Zhongshan Hospital | Huashan Hospital | Shanghai 10th People's Hospital | Shanghai 6th People's Hospital | Shanghai General Hospital | Shanghai East Hospital | Longhua Hospital | Second Affiliated Hospital, Soochow University | Affiliated Hospita"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            University of Alberta

                            Country arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            University of Alberta

                            Country arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sotatercept

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase IV

                            Sponsor : MERCK CANADA INC | Alberta Health services

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Sotatercept in Pulmonary Arterial Hypertension

                            Details : Sotatercept is a Protein drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Pulmonary Arterial Hypertension.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            August 24, 2025

                            Lead Product(s) : Sotatercept

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase IV

                            Sponsor : MERCK CANADA INC | Alberta Health services

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            SPH Qingdao Growful Pharmacetical Co.,Ltd

                            Country arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            SPH Qingdao Growful Pharmacetical Co.,Ltd

                            Country arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Yangxinshi

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study on the Treatment of CCD Combined with Cardiac Dysfunction with Yangxinshi Tablets

                            Details : Yangxinshi is a Plant Extract/Herbal drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Coronary Artery Disease.

                            Product Name : Undisclosed

                            Product Type : Plant Extract/Herbal

                            Upfront Cash : Inapplicable

                            August 07, 2025

                            Lead Product(s) : Yangxinshi

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            University of Florida

                            Country arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            University of Florida

                            Country arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Furosemide

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase IV

                            Sponsor : SQ Innovation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Gator SCALES-WHF: Subcutaneous Lasix to Eliminate Symptoms of Worsening HF

                            Details : Furosemide is a Other Small Molecule drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Heart Failure.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 20, 2025

                            Lead Product(s) : Furosemide

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase IV

                            Sponsor : SQ Innovation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Daiichi Sankyo

                            Japan arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Daiichi Sankyo

                            Japan arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bempedoic Acid

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Investigate the Effectiveness and Safety of Bempedoic Acid in Patients With Primary Hypercholestero...

                            Details : Bempedoic Acid is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hypercholesterolemia.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 13, 2025

                            Lead Product(s) : Bempedoic Acid

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            RDC Clinical

                            Australia arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            RDC Clinical

                            Australia arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Carotenoids

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase IV

                            Sponsor : Bio-gen Extracts

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            CaroRiteâ„¢ for Skin Health and Signs of Ageing

                            Details : Carotenoids is a Plant Extract/Herbal drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Aging.

                            Product Name : Undisclosed

                            Product Type : Plant Extract/Herbal

                            Upfront Cash : Inapplicable

                            March 14, 2025

                            Lead Product(s) : Carotenoids

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Bio-gen Extracts

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Sarfez Pharmaceuticals

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Sarfez Pharmaceuticals

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Torsemide

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Crossover Study of Patients with HF to Compare Natriuretic Effects of IR Torsemide Vs. ER Torsemide Over 12 ...

                            Details : Torsemide is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Heart Failure.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 27, 2024

                            Lead Product(s) : Torsemide

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Amsterdam UMC, VUmc

                            Country arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Amsterdam UMC, VUmc

                            Country arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sotatercept

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase IV

                            Sponsor : Merck & Co

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Right Ventricular Compensation with Sotatercept: a Prospective Single Arm Open Label Phase 4 Study to Evaluate...

                            Details : Sotatercept is a Protein drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Pulmonary Arterial Hypertension.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            October 26, 2024

                            Lead Product(s) : Sotatercept

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Merck & Co

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            CHA University

                            Country arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            CHA University

                            Country arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Colchicine

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase IV

                            Sponsor : Biotronik

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            MACT (Mono Antiplatelet and Colchicine Therapy) Prospective Multicenter Study

                            Details : Colchicine is a Plant Extract/Herbal drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Acute Coronary Syndrome.

                            Product Name : Undisclosed

                            Product Type : Plant Extract/Herbal

                            Upfront Cash : Inapplicable

                            August 07, 2024

                            Lead Product(s) : Colchicine

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Biotronik

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            AOP Orphan

                            Austria arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            AOP Orphan

                            Austria arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Treprostinil Sodium

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase IV

                            Sponsor : ANOVA CRO | PharmaLex | Aixial s.r.o. | GCP-Service International

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Initial Triple Therapy Including Parenteral Treprostinil vs Initial Double Oral Therapy in PAH Group I Patient...

                            Details : Treprostinil Sodium is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Pulmonary Arterial Hypertension.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 19, 2024

                            Lead Product(s) : Treprostinil Sodium

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase IV

                            Sponsor : ANOVA CRO | PharmaLex | Aixial s.r.o. | GCP-Service International

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Pharmasoft

                            Country arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Pharmasoft

                            Country arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Emoxypine Succinate

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            MEXIDOL® in the Rehabilitation Treatment of Patients With Acute Cerebral Failure

                            Details : Mexidol is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Ischemic Stroke.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 24, 2024

                            Lead Product(s) : Emoxypine Succinate

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth